High-dose chemotherapy with autologous stem cell transplantation for patients with extracranial germ cell tumors – experience of two Brazilian pediatric centers

References

• Young JL, Ries LG, Silverberg E, Horm JW, Miller RW. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer. 1986;58(2 Suppl):598–602. doi:10.1002/1097-0142(19860715)58:2+ <598::aid-cncr2820581332 > 3.0.co;2-c.
   PubMedGoogle Scholar
• Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst. 1999;91(12):1051–1058. doi:10.1093/jnci/91.12.1051.
   PubMed Web of Science ®Google Scholar
• Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer. 2010;116(20):4882–4891. doi:10.1002/cncr.25454.
   PubMed Web of Science ®Google Scholar
• Göbel U, Calaminus G, Schneider DT, Schmidt P, Haas RJ, MAKEI and MAHO Study Groups of the German Society of Pediatric Oncology and Hematology, and the SIOP CNS GCT Study Group. Management of germ cell tumors in children: approaches to cure. Onkologie. 2002;25(1):14–22. doi:10.1159/000055197.
   PubMedGoogle Scholar
• Olson TA, Murray MJ, Rodriguez-Galindo C, et al. Pediatric and adolescent extracranial germ cell tumors: the road to collaboration. J Clin Oncol. 2015;33(27):3018–3028. doi:10.1200/JCO.2014.60.5337.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Donohue JP. Chemotherapy for disseminated testicular cancer. Urol Clin North Am. 1977;4(3):407–426.
   PubMedGoogle Scholar
• Einhorn EH. Testicular cancer: an oncological success story. Clin Cancer Res. 1997;3(12 Pt 2):2630–2632.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16(7):2500–2504. doi:10.1200/JCO.1998.16.7.2500.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18(12):2413–2418. doi:10.1200/JCO.2000.18.12.2413.
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23(27):6549–6555. doi:10.1200/JCO.2005.19.638.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340–348. doi:10.1056/NEJMoa067749.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28(10):1706–1713. doi:10.1200/JCO.2009.25.1561.
   PubMed Web of Science ®Google Scholar
• Pagliaro LC. Role of high-dose chemotherapy with autologous stem-cell rescue in men with previously treated germ cell tumors. J Clin Oncol. 2017;35(10):1036–1040. doi:10.1200/JCO.2016.70.6523.
   PubMed Web of Science ®Google Scholar
• Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH. High-Dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J Clin Oncol. 2017;35(10):1096–1102. doi:10.1200/JCO.2016.69.5395.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25(3):247–256. doi:10.1200/JCO.2005.05.4528.
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Rosti G, Slavin S, European Group for Blood and Marrow Transplantation Solid Tumours and Paediatric Disease Working Parties, et al. Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours. Br J Cancer. 2005;93(4):412–417. doi:10.1038/sj.bjc.6602724.
   PubMed Web of Science ®Google Scholar
• Ussowicz M, Mielcarek-Siedziuk M, Musiał J, et al. Melphalan, etoposide, and carboplatin megatherapy with autologous stem cell transplantation in children with relapsing or therapy-resistant extracranial germ-cell tumors-a retrospective analysis. Cancers (Basel). 2020;12(12):E3841. doi:10.3390/cancers12123841.
   PubMed Web of Science ®Google Scholar
• Lopes LF, Macedo CRPD, Aguiar SDS, et al. Lowered cisplatin dose and no bleomycin in the treatment of pediatric germ cell tumors: results of the GCT-99 protocol from the Brazilian Germ Cell Pediatric Oncology Cooperative Group. J Clin Oncol. 2016;34(6):603–610. doi:10.1200/JCO.2014.59.1420.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. Available from URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40.
   Google Scholar
• Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(2):138–145. doi:10.1038/bmt.2017.161.
   PubMed Web of Science ®Google Scholar
• Lo Curto M, Lumia F, Alaggio R, et al. Malignant germ cell tumors in childhood: results of the first Italian cooperative study “TCG 91”. Med Pediatr Oncol. 2003;41(5):417–425. doi:10.1002/mpo.10324.
   PubMedGoogle Scholar
• Cushing B, Giller R, Cullen JW, Children’s Cancer Group 8882, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study–Pediatric Oncology Group 9049 and Children’s Cancer Group 8882. J Clin Oncol. 2004;22(13):2691–2700. doi:10.1200/JCO.2004.08.015.
   PubMed Web of Science ®Google Scholar
• Lopes LF, Macedo CR, Pontes EM, et al. Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91. J Clin Oncol. 2009;27(8):1297–1303. doi:10.1200/JCO.2008.16.4202.
   PubMed Web of Science ®Google Scholar
• Terenziani M, Bisogno G, Boldrini R, et al. Malignant ovarian germ cell tumors in pediatric patients: the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study. Pediatr Blood Cancer. 2017;64(11):e26568. doi:10.1002/pbc.26568.
   Web of Science ®Google Scholar
• Terenziani M, De Pasquale MD, Bisogno G, et al. Malignant testicular germ cell tumors in children and adolescents: the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) protocol. Urol Oncol. 2018;36(11):502.e7–502.e13. doi:10.1016/j.urolonc.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Faure-Conter C, Orbach D, Cropet C, et al. Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience. Pediatr Blood Cancer. 2014;61(2):253–259. doi:10.1002/pbc.24730.
   PubMed Web of Science ®Google Scholar
• Pashankar F, Frazier AL, Krailo M, et al. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: a report from the Children’s Oncology Group AGCT0521 study. Pediatr Blood Cancer. 2018;65(8):e27111. doi:10.1002/pbc.27111.
   PubMed Web of Science ®Google Scholar
• De Pasquale MD, D'Angelo P, Crocoli A, et al. Salvage treatment for children with relapsed/refractory germ cell tumors: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer. 2020;67(3):e28125. doi:10.1002/pbc.28125.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Huddart R, Hall E, Beyer J, Powles T. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J Cancer. 2011;2:374–377. doi:10.7150/jca.2.374.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst. 1993;85(22):1828–1835. doi:10.1093/jnci/85.22.1828.
   PubMedGoogle Scholar
• Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15(7):2546–2552. doi:10.1200/JCO.1997.15.7.2546.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Kollmannsberger C, Meisner C, et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol. 1999;17(11):3450–3456. doi:10.1200/JCO.1999.17.11.3450.
   PubMed Web of Science ®Google Scholar
• Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22(5):1054–1061. doi:10.1093/annonc/mdq575.
   PubMed Web of Science ®Google Scholar
• Necchi A, Mariani L, Di Nicola M, et al. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Ann Oncol. 2015;26(1):167–172. doi:10.1093/annonc/mdu485.
   PubMed Web of Science ®Google Scholar
• Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30(8):800–805. doi:10.1200/JCO.2011.38.6391.
   PubMed Web of Science ®Google Scholar
• Lotz JP, Bui B, Gomez F, Groupe d‘Etudes des Tumeurs Uro-Génitales (GETUG), et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol. 2005;16(3):411–418. doi:10.1093/annonc/mdi087.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Stiff PJ, Carreras J, et al. Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. Biol Blood Marrow Transplant. 2007;13(7):778–789. doi:10.1016/j.bbmt.2007.02.013.
   PubMed Web of Science ®Google Scholar
• Gössi F, Spahn M, Zweifel M, et al. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. Bone Marrow Transplant. 2017;52(2):334–336. doi:10.1038/bmt.2016.285.
   PubMed Web of Science ®Google Scholar